Newsroom

Sorted by: Latest

-

Valerio Therapeutics Completes Acquisition of Etherna Immunotherapies, Building an Integrated Targeted RNA Platform to Accelerate Progress Toward the Clinic

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News Valerio Therapeutics (FR0010095596 - ALVIO), a biotechnology company pioneering next-generation precision-guided RNA therapeutics ("Valerio" or the "Company"), today announces the completion of the acquisition of 100% of the share capital and voting rights of Etherna Immunotherapies NV ("Etherna") (the "Acquisition"). Further to the closing of the cash consideration of the Acquisition which occurred in August1, the Company has now proceeded to...
-

Valerio Therapeutics finalise l'acquisition d'Etherna Immunotherapies créant ainsi une plateforme intégrée d'ARN ciblés pour accélérer le développement vers le stade clinique

VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: Valerio Therapeutics (FR0010095596 - ALVIO), société de biotechnologie pionnière dans le domaine des thérapies de précision de nouvelle génération à base d’ARN ciblés (« Valerio » ou la « Société »), annonce aujourd’hui la réalisation de l’Acquisition de 100 % du capital social et des droits de vote d’Etherna Immunotherapies NV (« Etherna ») (l’« Acquisition »). À la suite du règlement de la contrepartie en numéraire de l'Acquisition, qui a e...
-

ABL Texcell Diagnostics Strengthens Its Presence at Genopole and Opens a New Chapter in Precision Oncology With the Acquisition of IntegraGen’s Assets and Operations

WOIPPY, France--(BUSINESS WIRE)--Regulatory News: ABL Texcell Diagnostics (Euronext Paris: ABLD – ISIN: FR001400AHX6), a company specializing in molecular diagnostic solutions, healthcare software, and services supporting clinical research and biopharmaceutical development, today announces the acquisition of IntegraGen’s assets and business operations (www.integragen.com, Euronext Growth Paris: ALINT – ISIN: FR0010908723), pursuant to the ruling handed down by the Evry Commercial Court on Frida...
-

ABL TEXCELL DIAGNOSTICS RENFORCE SON ANCRAGE AU GENOPOLE ET OUVRE UN NOUVEAU CHAPITRE DE DÉVELOPPEMENT EN ONCOLOGIE DE PRÉCISION AVEC LA REPRISE DES ACTIFS ET DES ACTIVITÉS D’INTEGRAGEN

WOIPPY, France--(BUSINESS WIRE)--Regulatory News: ABL Texcell Diagnostics (Euronext Paris : ABLD – ISIN : FR001400AHX6), société spécialisée dans les solutions de diagnostic moléculaire, les logiciels de santé et les services associés à la recherche clinique et au développement biopharmaceutique, annonce la reprise des actifs et activités d’IntegraGen (www.integragen.com, Euronext Growth Paris ALINT – ISIN : FR0010908723), conformément au jugement rendu le vendredi 9 octobre 2026 par le Tribuna...
-

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab (Poteligeo®) in Patients With Mycosis Fungoides and Sézary Syndrome

GALASHIELS, Scotland & MARLOW, England--(BUSINESS WIRE)--Kyowa Kirin International plc, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced final results from the German MINT study evaluating mogamulizumab in patients with mycosis fungoides (MF) and Sézary Syndrome (SS). Presented at the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group (EORTC-CLTG) Annual Meeting 2026 in Berlin, Germany, the findings represent one...
-

Pershing Square Holdings, Ltd. UK Regulatory Announcement: Transaction in Own Shares

LONDON--(BUSINESS WIRE)--  Pershing Square Holdings, Ltd. Announces Transactions in Own Shares - 9 October 2026 Pershing Square Holdings, Ltd. (LN:PSH) (LN:PSHD) (“PSH”) today announced that it has purchased, through PSH’s agent, Jefferies International Limited (“Jefferies”), the following number of PSH’s Public Shares of no par value (ISIN Code: GG00BPFJTF46) (the "Shares"): Total Buyback   Ticker/s: PSH (LSE); PSHD (LSE) Date of Purchase: 9 October 2026 Number of Public Shares Purchased: 29,5...
-

Pzena Investment Management, LLC UK Regulatory Announcement: Form 8.3 Tate & Lyle Plc

NEW YORK--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Pzena Investment Management, LLC (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries mus...
-

Megaport Expands Global Automated Infrastructure Platform Into Portugal

BRISBANE, Australia--(BUSINESS WIRE)--Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of its services in Portugal, expanding its European footprint and enabling enterprises and service providers in the region to connect instantly to the world’s leading cloud, network, and data center providers. With new on-ramps in Lisbon, customers in Portugal can now access Megaport’s automated infrastructure platform as well as more tha...
-

HAFNIA LIMITED: Mandatory Notification of Trade by Primary Insider

SINGAPORE--(BUSINESS WIRE)--Perry Van Echtelt, Chief Financial Officer of Hafnia Limited ("Hafnia", the "Company", OSE ticker code: "HAFNI", NYSE ticker code: "HAFN"), has on 9 October 2026 sold 50,000 shares in Hafnia at an average price of NOK 101.5203 per share on Oslo Børs. Following the share sale, Perry van Echtelt has a significant financial interest in the Company, holding a total of 563,544 shares and options. For more information see the attached mandatory notification of trade. This...
-

Advicenne étend son horizon de trésorerie jusqu’en 2028 grâce à son financement obligataire et à ses bonnes performances opérationnelles

PARIS--(BUSINESS WIRE)--Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), société pharmaceutique spécialisée dans le développement et la commercialisation de traitements innovants pour les personnes souffrant de maladies rénales rares, annonce aujourd’hui l’encaissement du solde du financement, d’un montant net de 1,0 M€, résultant de l’accord d’emprunt obligataire avec un fonds géré par L1 Capital1. Grâce à ce nouvel apport, Advicenne renforce sa trésorerie qui s’élevait...